Business Wire

Dr. Mike Durkin Assumes Role as Vice Chairman of Patient Safety Movement Foundation Board of Directors

Share

The Patient Safety Movement Foundation (PSMF), a global non-profit on a mission to achieve zero preventable patient deaths by 2030, has appointed Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc to serve as vice chairman of the board of directors. Dr. Durkin will work alongside Chairman Michael A.E. Ramsay, MD, FRCA to provide guidance and strategic support of the organization’s goal to create safer and more reliable healthcare systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005212/en/

Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc (Photo: Business Wire)

Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc (Photo: Business Wire)

“Dr. Durkin has been an invaluable member of the Patient Safety Movement Foundation board since he joined in 2018, and we are pleased he has accepted this leadership role,” said Dr. Ramsay. “His experience leading the National Patient Safety Improvement Programme for the National Health Service (NHS) England and work with the World Health Organization’s international development of patient safety systems make him an ideal fit to help lead our organization as we continue to grow globally.”

Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. From 2012 to 2017, he served as the national director of patient safety for England’s NHS. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities. He served as executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people, prior to becoming the national director in 2012. His passion for patient safety led him to assemble the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. In 2015, he was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019).

“I am honored to be appointed as vice chairman of the board of directors of the Patient Safety Movement Foundation,” states Durkin. “With the recent launch of our new commitment model and amid a global pandemic, I believe the healthcare industry across the globe is ready and prepared for change and I look forward to working alongside the leadership team to further our shared mission.”

Durkin was appointed officer of the Order of the British Empire (OBE) by Her Majesty The Queen for his services to patient safety and in 2018 was selected as an inaugural member of the International Academy of Safety and Quality. Durkin holds an honorary doctorate from the University of the West of England and he was awarded the highest accolade of the Royal College of Physicians of London for service to patient safety, their Honorary Fellowship in 2017. He is chair of the management board of NICE National Clinical Guideline Centre and sits on multiple national and international research, policy and patient safety advisory boards.

To learn more about the Patient Safety Movement Foundation and its leadership team, visit: https://patientsafetymovement.org/about/

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers and private payers together under the same cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org to learn more, and follow PSMF on Linkedin, Twitter, Instagram and Facebook.

Contact information

Media Contact
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kyoto Semiconductor Signs Supply and Reseller Agreement With CEL13.4.2021 03:00:00 CEST | Press release

Kyoto Semiconductor Co., Ltd., a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced that it has entered into an agreement with California Eastern Laboratories (CEL) to be a multinational reseller of Kyoto Semiconductor’s optical device solutions. The partnership extends Kyoto Semiconductor’s sales and support network not only to North America but to countries such as India and Israel while it enhances CEL’s product offering with Kyoto Semiconductor’s high-quality photodiodes for optical communication and sensing equipment “Kyoto Semiconductor is pleased to collaborate with CEL, one of the best suppliers of compound and silicon semiconductors, known for its superior customer support and technological expertise. With this partnership, we extend our customer reach worldwide, ranging from North America to India or Israel”, said Tsuneo Takahashi, CEO at Kyoto Semiconductor. “Our products are critical for the 5G and beyond-5G wirele

Bentley Systems Brings Infrastructure Digital Twins to NVIDIA Omniverse12.4.2021 19:00:00 CEST | Press release

GTC21 – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that it is developing applications using the NVIDIA Omniverse platform for photorealistic, real-time visualization and simulation of digital twins of massive-scale industrial and civil infrastructure projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005214/en/ Image courtesy of Houston Waterworks Team (a Joint Venture of Jacobs Engineering Group, Inc. and CDM Constructors, Inc.) Bentley Systems has extended the Bentley iTwin platform to integrate with NVIDIA Omniverse to provide a graphics pipeline for AI-enhanced, real-time visualization, and simulation of infrastructure digital twins. This integration allows engineering-grade, millimeter-accurate digital content to be visualized with photorealistic lighting and environmental effects on multiple devices including web browsers, workstations, tabl

QCT Unveils Optimized Accelerated Server to Boost High-Performance Workloads12.4.2021 19:00:00 CEST | Press release

Quanta Cloud Technology (QCT), a global data center solution provider, today announced a new addition to its broad portfolio of NVIDIA-Certified SystemsTM with its QuantaGrid D43N-3U. This server complements QCT’s existing high-performance QuantaGrid and QuantaPlex family of servers, while enabling customers the ability to leverage the latest next-generation NVIDIA Tensor Core GPUs for advanced AI workloads, including those that run on virtualized infrastructure with the NVIDIA AI Enterprise software suite. NVIDIA Tensor Core GPUs on QCT systems are built on the rich ecosystem of AI frameworks from the NVIDIA NGC catalog, CUDA-X libraries, over 2.3 million developers, and over 1,800 GPU-optimized applications to help enterprises solve the most critical challenges in their business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005024/en/ QuantaGrid_D43N-3U (Photo: Business Wire) “Utilizing NVIDIA accelerated computing

Mavenir Launches 5G Hyperconverged Edge AI Solution for Enterprise & Telco Market Based on NVIDIA Platforms12.4.2021 19:00:00 CEST | Press release

Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), announced today the launch of an AI-on-5G Hyper Converged Edge solution working in close collaboration with NVIDIA. Mavenir has developed this unique solution, based on NVIDIA’s hardware and software technologies, enabling Enterprises & Telcos to implement AI-on-5G applications for many promising verticals such as Manufacturing, Mining, and Healthcare that cover Industry 4.0 applications, including Industrial Internet of Things (IIoT), Intelligent Video Analytics (IVA) and Extended Reality (XR) and Gaming use cases. The use cases can be around remote and immersive collaboration, precision robotics control, people safety, intrusion detection, smart connected factories, real-time manufacturing component defect detection and proactive maintenance using near real-time analytics of sensor data. 5G enables an

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent12.4.2021 17:04:00 CEST | Press release

Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company’s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide. Results from a Phase II proof-of-concept study conducted by the US National Cancer Institute (NCI) (NCT02487095)* and published in Cancer Cell showed that berzosertib in combination with the chemotherapy topotecan resulted in an objective response rate (ORR) of 36% among patients with relapsed small cell lung cancer (SCLC), including durable responses among a majority of responding patients with platinum-resistant disease.1 The NCI is also conducting a separate Phase II trial of berzosertib in combination with topotecan versus topotecan monotherapy in SCLC that has relapsed (NCT03896503)* which

Loomis Sayles Welcomes Susan Sieker as Chief Financial Officer12.4.2021 16:15:00 CEST | Press release

Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Susan Sieker has joined Loomis Sayles as executive vice president and chief financial officer (CFO). She also joins the Loomis Sayles Board of Directors. Susan reports to Kevin Charleston, chairman and chief executive officer of Loomis Sayles, and will oversee the finance organization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005613/en/ Susan joins Loomis Sayles from Cambridge Associates, where she was the chief financial officer and oversaw financial planning and analysis, treasury, accounting operations, financial reporting, payroll and taxes. Prior to joining Cambridge Associates in 2012, Susan served in a variety of finance and risk leadership roles at Brinker International, including vice president and treasurer, vice president of global infrastructure, vice president of benefits, vice president of business assurance

Alira Health Strengthens Its Growth Strategy With a $35M Funding, Led by Creadev12.4.2021 15:00:00 CEST | Press release

Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences, announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach. “I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advanc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom